124 results
Page 2 of 7
8-K/A
EX-99.3
zp3p lxwhpza2u7rjez
4 Oct 22
Other Events
4:42pm
8-K
EX-99.1
jhobkfoj0pfoshj hfnm
15 Sep 22
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
9:16am
425
ybpsfw8
15 Aug 22
Business combination disclosure
6:46am
8-K
EX-99.3
1jxbsn1 u47rn
5 Aug 22
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:01pm
8-K
EX-99.2
2v6jl2yn pvlkc
5 Aug 22
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:01pm
424B3
0fzv0yl74
29 Jul 22
Prospectus supplement
4:06pm
425
bwzqqlb q6dlpb20uhzm
6 Jul 22
Business combination disclosure
4:05pm
425
p2l0r0of
9 Jun 22
Business combination disclosure
4:01pm
8-K
EX-99.2
gqkaqhji8xg 7afxkh
23 May 22
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
4:08pm
8-K
EX-99.2
ch4hfdn77
5 May 22
Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
12:00am
425
bcfvpiv
27 Apr 22
Business combination disclosure
5:26pm
8-K
EX-99.1
10q d0w3puotkw
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-99.2
8bw22krhddy3iio
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-99.1
ahl0sasrgm31cjt7y3f9
4 Nov 21
Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results
4:09pm